Join CBSET and our partner Cilcare at the Safety Pharmacology Society 2024 Annual Meeting, September 22-25, at the Town and Country Resort, San Diego, CA.
The Safety Pharmacology Society is working to bring a dynamic program featuring topics addressing the development and safe medical use of biologically active molecular entities.
CBSET and Cilcare will be in booth #208.
Related Publications:
Maximizing insights from nonclinical safety studies in the context of rising costs and changing regulations. Donald Hodges, Michael Stonerook, Dany Salvail, Sandrine Lemouton. Journal of Pharmacological and Toxicological Methods. Volume 128, July–August 2024, 107538.
Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, Gaëlle Naert. Frontiers in Molecular Neuroscience, May 2, 2024.
HEAR THIS! Potential Therapeutics for COVID-19 Should Be Tested for Auditory Safety. Michael Naimark, Director of Business Development, CBSET; Wahid Awad, PhD, Chief Business Officer, Cilcare. World Pharma Today, August 24, 2020.
Auditory Therapy, Ototoxicity, and GLP Compliance: Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve? Michael Naimark, Director of Business Development, CBSET; Marie-Pierre Pasdelou, founder and the Chief Development Officer, Cilcare. World Pharma Today, November 1, 2017.